

# EVALUATION AND FOLLOW-UP OF PAEDIATRIC PATIENT WITH SHORT BOWEL SYNDROME ON TREATMENT WITH TEDUGLUTIDE: CASE REPORT

M.T. GOMEZ SANCHEZ<sup>1</sup>, F.D. FERNANDEZ GINES<sup>1</sup>, B. SANCHEZ RODRIGUEZ<sup>1</sup>, D. GAMEZ TORRES<sup>1</sup>, M. SANCHEZ VALERA<sup>1</sup>, T. MORENO DIAZ<sup>1</sup>  
<sup>1</sup>H.U TORRECÁRDENAS, PHARMACY, ALMERIA, SPAIN.

## BACKGROUND

Teduglutide is a glucagon-like peptide (GLP-2) analog that increases the proliferation of intestinal mucosal cells causing an increase in the absorption surface area and a reduction in the volume of TPN.

## PURPOSE

To evaluate the effectiveness of teduglutide in a PN-dependent pediatric patient with SBS.

## MATERIALS AND METHODS

- Observational, retrospective and descriptive study
- The reduction of the volume of TPN until its withdrawal was analyzed




PEDIATRIC CASE

## RESULTS



- The initial volumen was 500 mL
- The volume decreased by 45.6% (272mL) after 14 months.
- Parenteral nutrition was suspended due to multiple complications after 22 months.



## CONCLUSION

In our case, the percentage of TPN volume reduction is higher compared to other studies collected in a recent meta-analysis from *Bioletto et al.* Moreover, the TPN was totally withdrawn in less time than described in some studies.

**BIBLIOGRAPHY** Bioletto *et al.* Efficacy of Teduglutide for Parenteral Support Reduction in Patients with Short Bowel Syndrome: A Systematic Review and Meta-Analysis. *Nutrients*. 2022 Feb 14;14(4):796. doi: 10.3390/nu14040796. PMID: 35215445; PMCID: PMC8880479.

